Targeted therapies and immunotherapies are the current standard of care to treat advanced stages of RCC (stages III and IV), which include the use of tyrosine kinase inhibitors (TKIs), such as sunitinib or axitinib, and immune checkpoint inhibitors (ICIs) such as nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4) for first-line and atezolizumab (anti-PD-L1) for second line of treatment.3 This evidence concerns the gene CD274 and renal cell carcinoma.